Abstract: The present invention relates to transdermal delivery systems, methods and kits that include an agent to penetrate the basement membrane, a membrane of the skin previously known to be difficult to penetrate. In particular, the formulation includes a basement membrane disruptor that reversibly denatures the basement membrane of the skin. The formulation of the present invention further includes having at least one penetration agent, at least one vaso-modulator, and at least one active ingredient. In an embodiment, the penetration agent includes a solvent, a lipophilic agent, a hydrophilic agent, wherein the basement membrane disruptor, the vaso-modulator, and the active ingredient pass through the stratum corneum and epidermis. The basement membrane disruptor allows the vaso-modulator and the active ingredient pass through the basement membrane to dermis. The active ingredient, once at the dermis, is delivered locally to the tissue or systemically to the blood stream.

Abstract: Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds that exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ while also exhibiting bystander activities towards nearby cells having lower expression of the moeity targeted by the Conjugate.

Abstract: Methods comprising the insertion of a uterine cervical device into the lower part of the uterine cavity and endocervix for decreasing the incidence of the human papillomavirus in women, mainly types 16 and 18, thus preventing the development of uterine cervical cancer; for modifying the cervical microbiota; for increasing leukocytes and protecting against sexually transmitted infections in women.

Abstract: A dental composition comprising doped T1O2 nanoparticles, and a curable resin material, wherein the curable resin material comprises a polymer precursor component, and wherein the dopant may be one or more of, for example, N (nitrogen), Ag (silver), F (fluorine), P (phosphorus), and P04 (phosphate). A method of using the dental composition in a dental application. The dental composition may be antibacterial in the absence of visible light or UV light.

Abstract: Provided is a method of imparting antibacterial and deodorant functions by reacting iodic acid, and a material that is given antibacterial and deodorant functions. The method of imparting antibacterial and deodorant function is as follows. Reacting iodate to a material that includes elements capable of producing iodate insoluble in water and non-toxic to a living body to form iodic acid of such elements on the surface of the material, thereby the iodate is made to be supported so that antibacterial and deodorant is possible without elution of said iodate to the outside.

Abstract: A gel and suppository and method to provide the gel and the suppository, are disclosed herein. The gel comprising: between 50 and 150 millimolar of lactic acid concentrate; and between 0.5 and 10 millimolar of hydrogen peroxide concentrate. The suppository comprising: between 22.5 and 67.5 milligrams of lactic acid concentrate; and between 1 and 20 milligrams of hydrogen peroxide concentrate.

Abstract: The present invention relates to bioinks based on undenatured collagen, kits containing the same, and methods of printing three-dimensional structures using the bioinks.

Abstract: The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.

Abstract: Combination therapies for treating cancer comprising administration of a topoisomerase-1 inhibitor and a PARP inhibitor are provided. The topoisomerase-1 inhibitor can be delivered as a liposomal formulation that provides for prolonged accumulation of the topoisomerase-1 inhibitor within a tumor relative to outside of the tumor. Therapeutic benefit can thereby be obtained by delaying the administration of the PARP inhibitor after each administration of a liposomal irinotecan formulation until the accumulation of the topoisomerase inhibitor in the tumor is sufficiently greater than outside the tumor to result in increased efficacy of the PARP inhibitor and topoisomerase inhibitor within the tumor, while reducing the peripheral toxicity of the combination therapy. The therapies disclosed herein are useful in the treatment of human cancers with solid tumors, including cervical cancer.

Abstract: A biobased fatty acid arginate may be synthesized according to the disclosed process by combining arginine and a fatty acid. The fatty acid arginate may have certain beneficial properties, such as surfactant properties or acting as an antimicrobial agent.

Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.

Abstract: The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

Abstract: This invention relates to a series of binuclear palladacycle compounds, and methods for the production of these compounds, that are suitable for use in the treatment of cancer. In particular embodiments, R1 is phenyl substituted with two occurrences of isopropyl, R2 is Cl, and R3 is independently one or more substituents selected from —O(CH2)2O(CH2)2OH, —O(CH2)2O(CH2)2O(CH2)2OH, —O(CH2)2OH, and —O(CH2)2O(CH2)2OCH3.

Abstract: An oral care composition comprising zinc phosphate, stannous fluoride, arginine or lysine and an organic acid buffer system, as well as methods of using the same.

Abstract: A method of detecting the presence of a cathinone moiety in a sample, such as a suspected illicit drug sample, which comprises contacting the sample with a solution comprising neocuproine, a source of copper(II) and a catalyst and observing a colour change, where present, that correlates with the presence of cathinone. The method is operable at environmental temperature. Mechanical elements may be employed to accelerate the colour change if desired.

Abstract: An oral care composition comprising zinc phosphate, stannous fluoride, an anionic polymer, and a basic amino acid, as well as methods of using the same.

Abstract: In one embodiment, a composition may include beeswax, Candelilla wax, oregano oil, glycerin, olive oil, arnica plant concentrate, and carbolic acid. In another embodiment, a method for treating an injury to an affected limb may include may include cleaning the affected limb, providing a water-based treatment composition, applying the water-based treatment composition to the affected limb, providing an oil-based treatment composition, and applying the oil-based treatment composition to the affected limb. The method may further include providing a gauze impregnated with a wax-based treatment composition and wrapping the impregnated gauze around the affected limb. The water-based treatment composition may include water, essence of oregano, and carbolic acid. The oil-based treatment composition may include glycerin, arnica plant concentrate, and carbolic acid. The wax-based treatment composition may include beeswax, Candelilla wax, arnica plant concentrate, and carbolic acid.

Abstract: Disclosed is a composition for treating a joint disease or a connective tissue disease, a composition for cartilage regeneration, or a composition for treating an inflammatory disease, each of the compositions containing dextran, poloxamer or a mixture thereof. The composition stays in the joint or connective tissue for a long time due to the shock-absorbing effect, coating effect or anti-inflammation effect, relieves the shock, covers a damaged portion in a specific manner thereto, or reduces inflammation of an adhered portion. Thus, the composition may be useful for the treatment of the joint disease, the connective tissue disease, or for the cartilage regeneration.

Abstract: The invention relates to novel a high-volume swelling hydrogel which comprises a plurality of pores which are defined by an interpenetrating network, and/or a semi-interpenetrating network and/or simple cross-linked arrangement of a plurality of one or more species of hydrophilic polymers, optionally together with one or more biocompatible polymers and optionally together with one or more plasticising agents, characterised in that at least some of the pores are at least partially collapsed and/or flattened, and further characterised in that the interpenetrating network and/or semi-interpenetrating network and/or cross-linked arrangement which defines the collapsed and/or flattened pores is substantially unbroken. The invention also relates to a process for preparing such hydrogels, and to their use as an appetite suppressant.

Abstract: This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.